Trial
NCT03075553
Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Mayo Clinic
Collaborators
National Cancer Institute (NCI)
Condition
Blastic Plasmacytoid Dendritic Cell Neoplasm
Intervention
Laboratory Biomarker Analysis
Why stopped
due to poor response
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-04-21